La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Clinuvel Pharmaceuticals Salute del bilancio
Salute finanziaria criteri di controllo 6/6
Clinuvel Pharmaceuticals has a total shareholder equity of A$178.7M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$211.7M and A$33.0M respectively. Clinuvel Pharmaceuticals's EBIT is A$43.8M making its interest coverage ratio -19.1. It has cash and short-term investments of A$174.4M.
Informazioni chiave
0%
Rapporto debito/patrimonio netto
AU$0
Debito
Indice di copertura degli interessi | -19.1x |
Contanti | AU$174.45m |
Patrimonio netto | AU$178.65m |
Totale passività | AU$33.03m |
Totale attività | AU$211.68m |
Aggiornamenti recenti sulla salute finanziaria
Nessun aggiornamento
Recent updates
If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity
Aug 11Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jun 27Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?
May 09Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Mar 24An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued
Nov 18Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now
Oct 20Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?
Jul 30Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate
Feb 27Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?
Dec 14This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid
Nov 03A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Sep 23Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today
Jul 23With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting
Apr 10Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?
Mar 06Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts
Feb 27What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?
Feb 20Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain
Feb 01Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)
Jan 14We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide
Dec 28Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 10What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition
Nov 21Analisi della posizione finanziaria
Passività a breve termine: CUV's short term assets (A$201.5M) exceed its short term liabilities (A$29.4M).
Passività a lungo termine: Le attività a breve termine di CUV ( A$201.5M ) superano le sue passività a lungo termine ( A$3.6M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: CUV is debt free.
Riduzione del debito: CUV has not had any debt for past 5 years.
Copertura del debito: CUV has no debt, therefore it does not need to be covered by operating cash flow.
Copertura degli interessi: CUV has no debt, therefore coverage of interest payments is not a concern.